Synagistics Limited — Capital/Financing Update 2022

Sep 19, 2022

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

==> picture [63 x 86] intentionally omitted <==

WEALTHKING INVESTMENTS LIMITED 華 科 資 本 有 限 公 司

(Incorporated in the Cayman Islands with limited liability) (Stock Code: 1140)

EXTENSION OF LONG STOP DATE OF SUBSCRIPTION OF NEW SHARES UNDER GENERAL MANDATE

Reference is made to the announcement of Wealthking Investments Limited (the ‘‘Company’’) dated 5 September 2022 (the ‘‘Announcement’’) in relation to subscription of 1,605,150,622 new Shares under General Mandate. Terms used herein shall have the same meanings as defined in the Announcement unless the context requires the otherwise.

Pursuant to the Subscription Agreement, Completion of the Subscription is conditional upon the fulfilment of the conditions precedent to the Subscription Agreement (the ‘‘Long Stop Date’’) on or prior to 19 September 2022 or such later date which may be agreed by the Company and the Subscriber.

As additional time is required for the fulfilment of the conditions precedent to the Subscription Agreement, the Company and the Subscriber have agreed to extend the Long Stop Date to on or prior to 26 September 2022. The parties have entered into the supplemental agreement for extension of the Long Stop Date, and save and except for the aforesaid, all other terms and conditions of the Subscription Agreement remain unchanged and in full force and effect in all respects.

By order of the Board Wealthking Investments Limited Liu Zhiwei Executive Director and Chairman

Hong Kong SAR, 19 September 2022

As at the date of this announcement, the Board comprises one executive Director, namely, Dr. Liu Zhiwei; two non-executive Directors, namely Dr. Fu Weigang and Dr. Wang Shibin; and three independent non-executive Directors, namely, Mr. Chen Yuming, Mr. Yan Xiaotian and Mr. Zhao Kai.